NASDAQ:VXRT - Vaxart Stock Price, Forecast & News

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Shares of Vaxart reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

Vaxart Inc (NASDAQ:VXRT) announced its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. The biotechnology company earned $0.45 million during the quarter, compared to analysts' expectations of $0.44 million. Vaxart had a negative net margin of 222.20% and a negative return on equity of 115.71%. View Vaxart's Earnings History.

Vaxart is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Vaxart.

2 equities research analysts have issued 1-year price objectives for Vaxart's stock. Their forecasts range from $2.00 to $6.00. On average, they anticipate Vaxart's stock price to reach $4.00 in the next year. This suggests a possible upside of 709.7% from the stock's current price. View Analyst Price Targets for Vaxart.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vaxart.

News stories about VXRT stock have trended very positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vaxart earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Vaxart.

Some companies that are related to Vaxart include Gamida Cell (GMDA), Polarityte (PTE), Acorda Therapeutics (ACOR), Brainstorm Cell Therapeutics (BCLI), Champions Oncology (CSBR), Surface Oncology (SURF), Pharmacyte Biotech (PMCB), BIONDVAX PHARMA/S (BVXV), Microbot Medical (MBOT), Allena Pharmaceuticals (ALNA), Genocea Biosciences (GNCA), Pluristem Therapeutics (PSTI), Curis (CRIS), Idera Pharmaceuticals (IDRA) and INmune Bio (INMB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Conatus Pharmaceuticals (CNAT), Cascadian Therapeutics (CASC), Dextera Surgical (DXTR), Novavax (NVAX), Opko Health (OPK), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX), Actinium Pharmaceuticals (ATNM), Anavex Life Sciences (AVXL) and Avid Bioservices (CDMO).

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VXRT stock can currently be purchased for approximately $0.49.

Vaxart has a market capitalization of $23.57 million and generates $4.16 million in revenue each year. The biotechnology company earns $-18,000,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Vaxart employs 34 workers across the globe.View Additional Information About Vaxart.

The official website for Vaxart is http://www.vaxart.com/.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]